Burden of respiratory syncytial virus infection in young children

Area of Science:

• Pediatrics
• Infectious Diseases
• Virology

Background:

• Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants and young children.
• Infection is seasonal, occurring during colder months in temperate regions and rainy seasons in tropical climates.
• Severe disease and mortality risk are elevated in specific high-risk infant populations.

Purpose of the Study:

• To summarize the epidemiology, risk factors, and current management strategies for Respiratory Syncytial Virus (RSV) infections in pediatric populations.
• To highlight the impact of RSV on long-term respiratory health and the current limitations in prevention and treatment.

Main Methods:

• Literature review of RSV epidemiology, clinical manifestations, and risk factors.
• Analysis of current immunoprophylaxis options and vaccine development status.

Main Results:

• RSV is a common pathogen, with significant morbidity in high-risk infants including premature infants, those with congenital heart disease, immunodeficiency, or neuromuscular disorders.
• While mortality is low in healthy infants, it increases with comorbidities. Long-term sequelae like recurrent wheezing and persistent lung function abnormalities can occur.
• No vaccine is currently available, but Palivizumab offers immunoprophylaxis for select high-risk infants, reducing disease burden.

Conclusions:

• RSV poses a substantial public health challenge, particularly for vulnerable infants.
• Effective prevention strategies, including a potential future vaccine and targeted immunoprophylaxis, are crucial for reducing RSV-related morbidity and mortality.
• Further research into long-term respiratory outcomes post-RSV infection is warranted.